- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Ben Saylor | Authors
Darolutamide Does Not Alter Metastatic Progression Pattern in nmCRPC in ARAMIS
June 07, 2022
Metastatic progression pattern with darolutamide appears to be unaltered in nonmetastatic castration-resistant prostate cancer, despite the agent resulting in better survival outcomes.
Data Support Safe Interaction of Darolutamide and Cabazitaxel in mCRPC
June 07, 2022
Unlike with enzalutamide, it appears darolutamide does not affect systemic exposure of cabazitaxel in patients with metastatic castration-resistant prostate cancer.
177Lu-PSMA-617 Has Similar Survival, But Increased PROs Vs Cabazitaxel in mCRPC
June 05, 2022
Similar overall survival, better patient-reported outcomes, and fewer adverse effects were observed when patients were treated with 177Lu-PSMA-617 vs cabazitaxel in metastatic castration-resistant prostate cancer.
Avelumab Maintenance Yields Survival Benefit in First-Line Advanced Urothelial Carcinoma, Regardless of Second-Line Therapy
June 04, 2022
An exploratory analysis of the JAVELIN Bladder 100 study indicated long-term overall survival benefit for patients with advanced urothelial carcinoma who received avelumab maintenace, without regard for treatment given in the second-line setting.
Cabozantinib After Chemotherapy Yields Similar Efficacy Vs Placebo in Advanced Urothelial Carcinoma
June 04, 2022
Results from the phase 2 ATLANTIS trial did not show a benefit of cabozantinib in patients with advanced urothelial carcinoma compared with the placebo, but the treatment appeared to be tolerable.
Disease-Free Survival Benefits Persist With Adjuvant Pembrolizumab in RCC
February 20, 2022
Updated data from the KEYNOTE-564 trial that were reported at 2022 ASCO GU show continuous disease-free survival advantage with pembrolizumab vs placebo as adjuvant therapy for renal cell carcinoma.
Patients With nmCRPC Continue to See Benefit With Darolutamide Despite Comorbidities, Concomitant Medications
February 17, 2022
Data from the ARAMIS trial that were presented at 2022 ASCO GU showed that darolutamide benefit for patients with nonmetastatic castration-resistant prostate cancer was consistent regardless of the number of comorbidities or concomitant medications.
Pembrolizumab/Olaparib Combo May Yield Better Responses in mCRPC Regardless of HRR Status
September 18, 2021
Patients with metastatic castration-resistant prostate cancer experienced an improvement in prostate-specific antigen following treatment with pembrolizumab and olaparib.
Abiraterone Plus ADT and Docetaxel to Treat de novo mCSPC Improved rPFS
June 09, 2021
Adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved radiographic progression-free survival for men with de novo metastatic castration-sensitive prostate cancer.
Lower Likelihood of Genomic Profiling Observed for Men With African Ancestry
June 08, 2021
Disparities regarding comprehensive genomic profiling came to light during a presentation at the 2021 ASCO Annual Meeting.